RAPT Therapeutics, Inc. (NASDAQ:RAPT) Receives $21.57 Consensus PT from Analysts

Shares of RAPT Therapeutics, Inc. (NASDAQ:RAPT) have been assigned a consensus recommendation of “Hold” from the eleven ratings firms that are covering the company, Marketbeat Ratings reports. Nine equities research analysts have rated the stock with a hold recommendation and two have assigned a buy recommendation to the company. The average 12 month target price among brokers that have issued a report on the stock in the last year is $21.57.

RAPT has been the topic of several analyst reports. Wolfe Research restated a “peer perform” rating on shares of RAPT Therapeutics in a report on Tuesday, May 14th. Barclays cut shares of RAPT Therapeutics from an “overweight” rating to an “equal weight” rating and cut their price target for the company from $13.00 to $4.00 in a report on Friday, May 10th. Guggenheim lowered shares of RAPT Therapeutics from a “buy” rating to a “neutral” rating in a report on Friday, May 10th. Finally, HC Wainwright reissued a “neutral” rating on shares of RAPT Therapeutics in a research report on Tuesday, August 20th.

Institutional Investors Weigh In On RAPT Therapeutics

A number of institutional investors have recently modified their holdings of the business. Point72 Asset Management L.P. boosted its stake in RAPT Therapeutics by 176,725.0% in the second quarter. Point72 Asset Management L.P. now owns 707,300 shares of the company’s stock valued at $2,157,000 after acquiring an additional 706,900 shares during the period. AQR Capital Management LLC bought a new stake in shares of RAPT Therapeutics in the 2nd quarter worth approximately $270,000. Squarepoint Ops LLC acquired a new position in RAPT Therapeutics during the 2nd quarter valued at approximately $329,000. Cubist Systematic Strategies LLC boosted its position in RAPT Therapeutics by 826.4% during the 2nd quarter. Cubist Systematic Strategies LLC now owns 295,241 shares of the company’s stock valued at $900,000 after purchasing an additional 263,372 shares during the period. Finally, XTX Topco Ltd bought a new position in RAPT Therapeutics during the 2nd quarter worth $108,000. Institutional investors own 99.09% of the company’s stock.

RAPT Therapeutics Trading Down 1.7 %

RAPT opened at $2.02 on Friday. RAPT Therapeutics has a twelve month low of $1.95 and a twelve month high of $27.35. The firm has a market cap of $70.50 million, a price-to-earnings ratio of -0.66 and a beta of 0.36. The company has a fifty day simple moving average of $2.79 and a 200 day simple moving average of $5.49.

RAPT Therapeutics (NASDAQ:RAPT) last announced its earnings results on Thursday, August 8th. The company reported ($0.71) earnings per share for the quarter, beating the consensus estimate of ($0.74) by $0.03. On average, analysts forecast that RAPT Therapeutics will post -2.73 earnings per share for the current fiscal year.

RAPT Therapeutics Company Profile

RAPT Therapeutics, Inc, a clinical-stage immunology-based biopharmaceutical company, focuses on discovery, development, and commercialization of oral small molecule therapies for patients with unmet needs in oncology and inflammatory diseases in the United States. The company's lead inflammation drug candidate is zelnecirnon (RPT193), a C-C motif chemokine receptor 4 (CCR4) antagonist that selectively inhibit the migration of type 2 T helper cells into inflamed tissues.